Last reviewed · How we verify
NgG HTD investigational vaccine
NgG HTD investigational vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | NgG HTD investigational vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NgG HTD investigational vaccine CI brief — competitive landscape report
- NgG HTD investigational vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about NgG HTD investigational vaccine
What is NgG HTD investigational vaccine?
NgG HTD investigational vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes NgG HTD investigational vaccine?
NgG HTD investigational vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is NgG HTD investigational vaccine in?
NgG HTD investigational vaccine is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: NgG HTD investigational vaccine vs similar drugs
- Pricing: NgG HTD investigational vaccine cost, discount & access